Holen Sie sich die Stockscreener-App
9.42
3.38%
-0.34
Schlusskurs vom Vortag:
$9.76
Offen:
$9.67
24-Stunden-Volumen:
225.15K
Relative Volume:
0.09
Marktkapitalisierung:
$626.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-297.11M
KGV:
-1.815
EPS:
-5.19
Netto-Cashflow:
$-216.95M
1W Leistung:
-13.49%
1M Leistung:
+134.58%
6M Leistung:
+25.73%
1J Leistung:
-8.71%
1-Tages-Spanne:
$9.35
$9.7099
1-Wochen-Bereich:
$8.86
$11.21
52-Wochen-Spanne:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
9.43 | 626.23M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.75 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.29 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.77 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
267.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
FDA Approval for VOQUENZA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC - Quantisnow
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom Pharmaceuticals Announces FDA Correction to Orange - GlobeNewswire
Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update - MarketScreener
Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA - Nasdaq
Phathom Pharmaceuticals Announces FDA Correction to Orange Book - GuruFocus
Phathom Pharmaceuticals (PHAT) Secures Extended Exclusivity for VOQUEZNA | PHAT Stock News - GuruFocus
FDA extends Phathom’s VOQUEZNA exclusivity period to 2032 By Investing.com - Investing.com Canada
FDA Grants 10-Year Exclusivity for Breakthrough GERD Drug VOQUEZNA: Major Win for Phathom - Stock Titan
Transcript : Phathom Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade - MSN
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy (PHAT) - Seeking Alpha
Phathom Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Phathom Pharmaceuticals (PHAT) Price Target Increased Following FDA Ruling | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Receives Buy Rating from HC Wainw - GuruFocus
Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals (PHAT) Analyst Rating Update: Price Target Raised to $17.00 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald - MSN
Phathom Pharmaceuticals (PHAT) Soars on FDA Approval and Market Exclusivity | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update - GuruFocus
FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT - GuruFocus
FDA Grants Phathom Pharmaceuticals (PHAT) Extended Exclusivity f - GuruFocus
Phathom Pharmaceuticals (PHAT) Surges 90% After FDA Grants 10-Year Exclusivity for Voquezna - Wealth Daily
Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity - TipRanks
Phathom Pharmaceuticals (PHAT) Receives Continued Buy Rating fro - GuruFocus
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna - Benzinga
Phathom Pharmaceuticals Gains Momentum with FDA Approval and Market Exclusivity for Voquezna - TipRanks
Needham sees FDA’s positive CP ruling as best-case outcome for Phathom - TipRanks
Phathom Pharmaceuticals Rides High On FDA's Drug Approval - Finimize
Phathom Soars 95% on FDA Exclusivity for VOQUEZNA - Wall Street Pit
Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity - Investing.com
Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity By Investing.com - Investing.com UK
PHAT Stock Target Raised Amid Extended Drug Exclusivity | PHAT S - GuruFocus
Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock By Investing.com - Investing.com Canada
Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock - Investing.com
PHAT Stock Target Raised Amid Extended Drug Exclusivity | PHAT Stock News - GuruFocus
Stifel expects Phathom to ‘largely recover ground lost’ after FDA grants claim - TipRanks
PHAT Stock: Phathom Pharmaceuticals Stock Surges 128% as FDA Grants 10-Year Exclusivity for Voquezna - gondwanauniversity.org
FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Says FDA Approves Co's Petition For 10 Years Exclusivity For Voquezna - MarketScreener
Phathom Pharmaceuticals (PHAT) Soars 125% on FDA Decision - GuruFocus
Phathom Pharmaceuticals Announces Positive FDA Decision to Recog - GuruFocus
Phathom Pharmaceuticals Shares Surge After FDA Grants 10-Year Exclusivity for Acid-Reducing Drug - marketscreener.com
Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032 | PHAT Stock News - GuruFocus
Phathom says FDA to correct Orange Book for Voquenza exclusivity - TipRanks
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory ... - Bluefield Daily Telegraph
Phathom Pharmaceuticals Announces Positive FDA Decision to - GlobeNewswire
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for Vquezna®? Tablets Through May 3, 2032 - MarketScreener
Phathom Pharmaceuticals shares soar on FDA exclusivity grant By Investing.com - Investing.com Nigeria
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
| Parikh Asit | Director |
Sep 10 '24 |
Option Exercise |
11.72 |
7,500 |
87,900 |
93,000 |
| Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
| Henderson Molly | CFO and CBO |
Jan 21 '25 |
Sale |
6.59 |
6,583 |
43,371 |
93,546 |
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):